About PEP-Therapy

PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology based on the Company’s innovative Cell Penetrating and Interfering Peptides (CP&IP) technology.

These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, leading to the inhibition of key pathological mechanisms without altering physiological mechanisms.

PEP-010, first CP&IP-based anti-cancer product, is entering Phase Ia/b clinical trials in partnership with Institut Curie and Gustave Roussy, leading European cancer centers.

PEP-Therapy, which was founded in 2014 and builds on research from Sorbonne University and Institut Curie, is backed by international investors: Italian Angels for Growth (IAG), Doorway, Magna Capital Partner (MCP), Business Angels des Grandes Ecoles (BAdGE), Seventure Partners (Quadrivium 1 Seed Fund) and Dr. Bernard Majoie (former Chairman and CEO of Laboratoires Fournier, Founding Chairman of Fournier-Majoie Foundation for Innovation).